If you’ve heard from your doctor that your lupus or lupus nephritis is treatment-resistant, keep reading to learn about a potential clinical study for you.
Get StartedYou may be eligible to participate in this study if you:
‘Refractory’ means your condition does not respond to standard treatment options or improve despite trying different medications.
Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.
The Frontier Study aims to assess two study drugs to understand their safety, tolerability and effectiveness on active and refractory lupus and lupus nephritis.
This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility.
Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.
PatientWing is helping identify potential individuals who may be interested in the Frontier study. You will have a short call with PatientWing to answer additional questions about your medical history and PatientWing will help collect your medical records.
After your conversation with PatientWing, you will meet the research team who will review your medical records.
If the research team thinks you are eligible, they will schedule a screening visit.
The research team will provide more information during your conversations with them. No question is a bad question so please share your concerns with the team!
After you've completed the screening period, the research team will notify you about your eligibility.
If you are enrolled in the Frontier Subprotocol A Study, you should expect the following:
If you are enrolled in the Subprotocol B Frontier Study, you should expect the following:
Participation in this study will not come at an additional cost to you. Reasonable expenses such as travel and parking may be reimbursed within reasonable limits.
Fill out the questionnaire and provide basic information to express interest in the study. You can also email studies@patientwing.com or call/text: 213-459-2979.
We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you need at every step. We are here to support your journey with clinical research!
The study drug will be given as subcutaneous injection once a week.
If you are enrolled in the Frontier Subprotocol A Study, you will visit the study site approximately 10 times over 12 months. If you are enrolled in the Subprotocol B Frontier Study, you will visit the study site approximately 20 times over 12 months.
Your participation may be about 13 months.
No, this study does not have a placebo. You will receive the study drug, Blinatumomab, if you participate in the study.
